Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Yale University
Dana-Farber Cancer Institute
Mayo Clinic
AstraZeneca
AstraZeneca